Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1995 2
1996 1
1997 1
1998 2
1999 2
2000 3
2001 1
2002 1
2003 1
2004 3
2005 5
2006 2
2007 2
2008 3
2009 1
2013 1
2014 2
2015 2
2016 5
2017 5
2018 4
2019 3
2020 5
2021 4
2022 6
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

60 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for pradines a
Search for Pradine A instead (1 results)
Switch to fulvestrant and palbociclib versus no switch in advanced breast cancer with rising ESR1 mutation during aromatase inhibitor and palbociclib therapy (PADA-1): a randomised, open-label, multicentre, phase 3 trial.
Bidard FC, Hardy-Bessard AC, Dalenc F, Bachelot T, Pierga JY, de la Motte Rouge T, Sabatier R, Dubot C, Frenel JS, Ferrero JM, Ladoire S, Levy C, Mouret-Reynier MA, Lortholary A, Grenier J, Chakiba C, Stefani L, Plaza JE, Clatot F, Teixeira L, D'Hondt V, Vegas H, Derbel O, Garnier-Tixidre C, Canon JL, Pistilli B, André F, Arnould L, Pradines A, Bièche I, Callens C, Lemonnier J, Berger F, Delaloge S; PADA-1 investigators. Bidard FC, et al. Among authors: pradines a. Lancet Oncol. 2022 Nov;23(11):1367-1377. doi: 10.1016/S1470-2045(22)00555-1. Epub 2022 Sep 29. Lancet Oncol. 2022. PMID: 36183733 Clinical Trial.
Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients: study design of PADA-1.
Berger F, Marce M, Delaloge S, Hardy-Bessard AC, Bachelot T, Bièche I, Pradines A, De La Motte Rouge T, Canon JL, André F, Arnould L, Clatot F, Lemonnier J, Marques S, Bidard FC; PADA-1 investigators. Berger F, et al. Among authors: pradines a. BMJ Open. 2022 Mar 3;12(3):e055821. doi: 10.1136/bmjopen-2021-055821. BMJ Open. 2022. PMID: 35241469 Free PMC article. Clinical Trial.
Molecular biomarkers for lung adenocarcinoma.
Calvayrac O, Pradines A, Pons E, Mazières J, Guibert N. Calvayrac O, et al. Among authors: pradines a. Eur Respir J. 2017 Apr 5;49(4):1601734. doi: 10.1183/13993003.01734-2016. Print 2017 Apr. Eur Respir J. 2017. PMID: 28381431 Free article. Review.
Diagnosis, biology and epidemiology of oligometastatic breast cancer.
Lacaze JL, Aziza R, Chira C, De Maio E, Izar F, Jouve E, Massabeau C, Pradines A, Selmes G, Ung M, Zerdoud S, Dalenc F. Lacaze JL, et al. Among authors: pradines a. Breast. 2021 Oct;59:144-156. doi: 10.1016/j.breast.2021.06.010. Epub 2021 Jul 1. Breast. 2021. PMID: 34252822 Free PMC article. Review.
Identification of a Circulating MicroRNA Profile as a Biomarker of Metastatic Cutaneous Melanoma.
Armand-Labit V, Meyer N, Casanova A, Bonnabau H, Platzer V, Tournier E, Sansas B, Verdun S, Thouvenot B, Hilselberger B, Doncescu A, Lamant L, Lacroix-Triki M, Favre G, Pradines A. Armand-Labit V, et al. Among authors: pradines a. Acta Derm Venereol. 2016 Jan;96(1):29-34. doi: 10.2340/00015555-2156. Acta Derm Venereol. 2016. PMID: 26039581 Free article.
How far we have come targeting BRAF-mutant non-small cell lung cancer (NSCLC).
Tabbò F, Pisano C, Mazieres J, Mezquita L, Nadal E, Planchard D, Pradines A, Santamaria D, Swalduz A, Ambrogio C, Novello S, Ortiz-Cuaran S; BOLERO Consortium. Tabbò F, et al. Among authors: pradines a. Cancer Treat Rev. 2022 Feb;103:102335. doi: 10.1016/j.ctrv.2021.102335. Epub 2021 Dec 31. Cancer Treat Rev. 2022. PMID: 35033867 Review.
Minimal Residual Disease Monitoring Using a 3'ALK Universal Probe Assay in ALK-Positive Anaplastic Large-Cell Lymphoma: ddPCR, an Attractive Alternative Method to Real-Time Quantitative PCR.
Quelen C, Grand D, Sarot E, Brugières L, Sibon D, Pradines A, Laurent C, Brousset P, Lamant L. Quelen C, et al. Among authors: pradines a. J Mol Diagn. 2021 Feb;23(2):131-139. doi: 10.1016/j.jmoldx.2020.11.002. Epub 2020 Nov 24. J Mol Diagn. 2021. PMID: 33246076 Free article.
Epigenetically regulated PCDHB15 impairs aggressiveness of metastatic melanoma cells.
Carrier A, Desjobert C, Lobjois V, Rigal L, Busato F, Tost J, Ensenyat-Mendez M, Marzese DM, Pradines A, Favre G, Lamant L, Lanfrancone L, Etievant C, Arimondo PB, Riond J. Carrier A, et al. Among authors: pradines a. Clin Epigenetics. 2022 Nov 28;14(1):156. doi: 10.1186/s13148-022-01364-x. Clin Epigenetics. 2022. PMID: 36443814 Free PMC article.
60 results